Allakos Receives $32,000,000 Series A Funding Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=28514a7b-3e38-484f-a66f-3863db024821&Preview=1 -
Date
12/18/2012 -
Company Name
Allakos -
Mailing Address
Undisclosed San Francisco, CA 94105 -
Company Description
Allakos Inc. is a privately held, product-focused biotechnology company developing first-in-class antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 (Th2) immune response plays a key role in pathology, including allergic disease, inflammation and diseases characterized by excess production of inflammatory cells. Allakos has generated a preclinical pipeline of novel antibodies targeting cell types implicated in allergic and inflammatory responses, which it intends to advance to clinical proof-of-concept. -
Website
http://www.allakos.com -
Transaction Type
Venture Equity -
Transaction Amount
$32,000,000 -
Transaction Round
Series A -
Proceeds Purposes
Proceeds purposes were not disclosed. -
M&A Terms
-
Venture Investor
Novo A/S -
Venture Investor
Alta Partners -
Venture Investor
RiverVest Venture Partners -
Venture Investor
Roche Venture Fund
